Comparison of agar dilution, disk diffusion, MicroScan, and Vitek antimicrobial susceptibility testing methods to broth microdilution for detection of fluoroquinolone-resistant isolates of the family Enterobacteriaceae

Journal of Clinical Microbiology

Volumn 37, Issue 3, 1999, Pages 544-547

  Steward, Christine D ^a,c   Stocker, Sheila A ^a   Swenson, Jana M ^a   O'Hara, Caroline M ^a   Edwards, Jonathan R ^a   Gaynes, Robert P ^a   McGowan Jr , John E ^b   Tenover, Fred C ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b EMORY UNIVERSITY   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; ANTIINFECTIVE AGENT; CIPROFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACCURACY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASSAY; BACTERIUM ISOLATE; CONTROLLED STUDY; DIFFUSION; DILUTION; ENTEROBACTERIACEAE; INTERMETHOD COMPARISON; NONHUMAN; PRIORITY JOURNAL;

BACTERIA (MICROORGANISMS); ENTEROBACTERIACEAE; NEGIBACTERIA;

EID: 0032996475     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.37.3.544-547.1999     Document Type: Article

References (26)

1. Acar, J. F., and F. W. Goldstein. 1997. Trends in bacterial resistance to fluoroquinolones. Clin. Infect. Dis. 24(Suppl. 1):S67-S73.
2. Andriole, V.T. 1998. Quinolones, p. 283-285. In S. L. Gorbach, J. G. Bartlett, and N. R. Blackow (ed.), Infectious diseases. W. B. Saunders Company, Philadelphia, Pa.
3. Blondeau, J. M., Y. Yaschuk, and the Canadian Ciprofloxacin Study Group. 1996. Canadian ciprofloxacin susceptibility study: comparative study from 15 medical centers. Antimicrob. Agents Chemother. 40:1729-1732.
4. Brenner, D. J., J. J. Farmer III, G. R. Fanning, A. G. Steigerwalt, P. Klykken, H. G. Wathen, F. W. Hickman, and W. H. Ewing. 1978. Deoxyribonucleic acid relatedness of Proteus and Providencia species. Int. J. Syst. Bacteriol. 28:269-282.
5. Cohen, M. A., M. D. Huband, J. W. Gage, S. L. Yoder, G. E. Roland, and S. J. Gracheck. 1997. In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin. J. Antimicrob. Chemother. 40:205-211.
6. Doern, G. V., B. B. Torres, M. Jankins, and R. N. Jones. 1996. Accurate characterization of ofloxacin susceptibility with Enterobacteriaceae using a modified GNS F6 card and the bioMérieux Vitek system. Diagn. Microbiol. Infect. Dis. 25:133-135.
7. Drlica, K., and X. Zhao. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61:377-392.
8. Dupeyron, C., N. Mangeney, L. Sedrati, B. Campillo, P. Fouet, and G. Leluan. 1994. Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous peritonitis. Antimicrob. Agents Chemother. 38:340-344.
9. Everett, M. J., Y. F. Jin, V. Ricci, and L. J. V. Piddock. 1996. Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob. Agents Chemother. 40:2380-2386.
10. Farmer, J. J., III, M. A. Asbury, F. W. Hickman, D. J. Brenner, and the Enterobacteriaceae Study Group. 1980. Enterobacter sakazakii: a new species of "Enterobacteriaceae" isolated from clinical specimens. Int. J. Syst. Bacteriol. 30:569-584.
11. Forbes, B. A., D. F. Sahm, and A. S. Weissfeld. 1998. Enterobacteriaceae, p. 509-526. In Bailey and Scott's diagnostic microbiology. Mosby, St. Louis, Mo.
12. Heisig, P. 1996. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob. Agents Chemother. 40:879-885.
13. Hooper, D. C. 1995. Bacterial resistance to fluoroquinolones: mechanisms and patterns, p. 49-57. In D. L. Jungkind (ed.). Antimicrobial resistance: a crisis in health care. Plenum Press, New York, N.Y.
14. Hooper, D. C., and J. S. Wolfson. 1991. Fluoroquinolone antimicrobial agents. N. Engl. J. Med. 324:384-394.
15. Kim, J. H., E. H. Cho, K. S. Kim, H. Y. Kim, and Y. M. Kim. 1998. Cloning and nucleotide sequence of the DNA gyrA gene from Serratia marcescens and characterization of mutations in gyrA of quinolone-resistant isolates. Anti-microb. Agents Chemother. 42:190-193.
16. Kleinbaum, D. G., L. L. Kupper, and H. Morgenstern. 1982. Epidemiologic research. Van Nostrand Reinhold, New York, N.Y.
17. Lehmann, E. L. 1975. Nonparametrics: statistical methods based on ranks. Holden-Day, Oakland, Calif.
18. Mirelis, B., E. Miro, F. Navarro, C. A. Ogalla, J. Bonal, and G. Prats. 1993. Increased resistance to quinolone in Catalonia, Spain. Diagn. Microbiol. Infect. Dis. 16:137-139.
19. Monnet, D., L. Archibald, L. Phillips, F. C. Tenover, J. E. McGowan, Jr., R. P. Gaynes, the Intensive Care Antimicrobial Resistance Epidemiology Project, and the National Nosocomial Infections Surveillance System Hospitals. 1998. Antimicrobial use and resistance in eight U.S. hospitals: complexities of analysis and modeling. Infect. Control Hosp. Epidemiol. 19:388-394.
20. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
21. National Committee for Clinical Laboratory Standards. 1997. Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
22. Ouabdesselam, S., D. C. Hooper, J. Tankovic, and C. J. Soussy. 1995. Detection of gyrA and gyrB mutations in quinolone-resistant clinical isolates of Escherichia coli by single-strand conformational polymorphism analysis and determination of levels of resistance conferred by two different single gyrA mutations. Antimicrob. Agents Chemother. 39:1667-1670.
23. Rothman, K. J. 1986. Modern epidemiology. Little, Brown and Company, Boston, Mass.
24. Spangler, S. K., M. A. Visalli, M. R. Jacobs, and P. C. Appelbaum. 1996. Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem. Antimicrob. Agents Chemother. 40:772-775.
25. Visalli, M. A., S. Bajaksouzian, M. R. Jacobs, and P. C. Appelbaum. 1997. Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods. Antimicrob. Agents Chemother. 41:1475-1481.
26. Waites, K., K. Rand, S. Jenkins, B. Yangco, E. Brookings, D. Gaskins, J. Lewis, and K. Halkias. 1994. Multicenter in vitro comparative study of fluoroquinolones after four years of widespread clinical use. Diagn. Microbiol. Infect. Dis. 18:181-189.